

RECEIVED

SEP 09 2002

TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Hagit AMITAI, et al
Serial No.: 09/807,610

Filed: April 16, 2001

For: EXPRESSION AND SECRETION OF ICIL-1 RECEPTOR ANTAGONIST TYPE II

Art Unit: 1646

Examiner: Ruixiang Li

Washington, D.C.

Atty.'s Docket: AMITAI=1

Date: September 6, 2002

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

Transmitted herewith is a [] Amendment [XX] Response to Restriction Requirement
in the above-identified application.

- [] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.
[] No additional fee is required.
[] The fee has been calculated as shown below:

	(Col. 1) CLAIMS REMAINING AFTER AMENDMENT	(Col. 2) MINUS	(Col. 3) HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	*	MINUS	** 20	0
INDEP.	*	MINUS	*** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

ADDITIONAL FEE TOTAL \$

SMALL ENTITY		OR	OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE		RATE	ADDITIONAL FEE
x 9	\$		x 18	\$
x 42	\$		x 84	\$
+ 140	\$		+ 280	\$
		OR		
				TOTAL \$

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
*** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

- [] First - \$ 55.00
[] Second - \$ 200.00
[] Third - \$ 460.00
[] Fourth - \$ 720.00

Month After Time Period Set

[] Less fees (\$_____) already paid for ____ month(s) extension of time on _____.

Other Than Small Entity

Response Filed Within

- [] First - \$ 110.00
[] Second - \$ 400.00
[] Third - \$ 920.00
[] Fourth - \$ 1440.00

Month After Time Period Set

[] Please charge my Deposit Account No. 02-4035 in the amount of \$_____.


[] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$_____.

[] A check in the amount of \$_____ is attached (check no.).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

By: 
Roger L. Browdy
Registration No. 25,618

Facsimile: (202) 737-3528
Telephone: (202) 628-5197



RECEIVED

SEP 09 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: AMITAI=1

In re Application of:) Conf. No.: 2065
Hagit AMITAI, et al)
Appln. No.: 09/807, 610) Art Unit: 1646
Filed: April 16, 2001) Examiner: Ruixiang Li
For: EXPRESSION AND SECRETION) Washington, D.C.
OF ICIL-1 RECEPTOR)
ANTAGONIST TYPE II) September 6, 2002

#67
9/13/02

RESPONSE

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

The present communication is responsive to the Official action of August 6, 2002. Claims 1-15 presently appear in this case. All of the claims have been subject to a restriction requirement. Reconsideration and withdrawal of the restriction requirement and examination on the merits and allowance of all the claims now present in the case is respectfully urged.

The examiner has required restriction among the following three groups:

Group I, including claims 1-12, drawn to an expression vector, a host cell, a recombinant icIL-1ra-II, a method for producing icIL-1ra-II, and a pharmaceutical composition comprising same;

Group II, including claim 13, drawn to a method for reducing the amount of IL-1 in a patient by administering a

pharmaceutical composition comprising the glycosylated icIL-1ra-II;
and

Group III, including claims 14 and 15, drawn to a method
for reducing the amount of IL-1 at a desired site in a human patient
by introducing an expression vector into an appropriate endogenous
human cell at the desired site to produce transformed cells which
will express icIL-1ra-II.

The examiner states that the Groups do not relate to a
single general inventive concept because the technical feature
linking Groups I to III appears to be the intracellular IL-1
receptor antagonist and the nucleic acid encoding same while the
prior art teaches cloning and characterization of an intracellular
form of the human interleukin-1 receptor antagonist, citing Haskill
and Muzio. This restriction requirement is respectfully traversed.

Haskill and Muzio relate only to the intracellular form
of the IL-1 receptor antagonist. However, the single general
inventive concept of the present invention is the provision of an
expression vector which includes a signal peptide joined to the DNA
segment of the prior art. All of the claims include this expression
vector and rely on this expression vector or the novel glycosylated
protein expressed therefrom, as a special technical feature. It is
not disclosed or made obvious by either of the references cited by
the examiner, both of which were only cited as being in Category A
by the international examiner. The DNA encoding the endogenous
intracellular protein has no signal peptide and was found to be
expressed constitutively intracellularly only. Reference is made to

the background of the invention and the detailed description of the present invention, particularly at pages 4 and 5.


In order to be responsive, applicant hereby elects the invention of Group I with traverse. At least the first method of use as set forth in Group II, should be examined with the claims of Group I. Furthermore, it would not create a serious burden for the examiner to also search and examine claims 14 and 15 on the merits so that all of the claims may be examined and issued from a single application.

Accordingly, reconsideration and withdrawal of the restriction requirement and prompt examination on the merits and allowance of all the claims now present in the case is earnestly solicited.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.
Attorneys for Applicant(s)

By


Roger L. Browdy
Registration No. 25,618

RLB:wlm
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
G:\BN\I\intp\AMITAI1\PTO\Response.doc